<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04741841</url>
  </required_header>
  <id_info>
    <org_study_id>GM_ME/CFS_2020SE</org_study_id>
    <nct_id>NCT04741841</nct_id>
  </id_info>
  <brief_title>Effect of Probiotics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)</brief_title>
  <official_title>Effect of Probiotic Food Supplement &quot;GutMagnific™&quot; in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), Also Known as Post-viral Fatigue Syndrome, and Comorbid Gastrointestinal Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmuneBiotech Medical Sweden AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ImmuneBiotech Medical Sweden AB</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a neurological disease.&#xD;
      Currently there is no effective treatment for ME/CFS due to unclear etiology of the disease.&#xD;
      The aim of this randomized double-blind placebo-control clinical trial is to study the&#xD;
      efficacy of the probiotic food supplement &quot;GutMagnific™&quot; in ME/CFS and comorbid&#xD;
      gastrointestinal complications. The outcome of the study will be assessed based on the data&#xD;
      from different self-reporting questionnaires and intestinal microbial flora analysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) is a neurological disease with&#xD;
      different symptoms such as fatigue. Symptoms get worse by physical or mental exertion which&#xD;
      usually persists for more than 24 hours (post-exertional malaise, PEM). ME/CFS is often&#xD;
      characterized by reduced functional capacity, worsening social relationships and reduced&#xD;
      ability to cope with work or study.&#xD;
&#xD;
      The exact cause of the ME/CFS is presently unknown however a history of viral infection is&#xD;
      common among ME/CFS patients. Prolonged post viral fatigue can develop into a chronic illness&#xD;
      and ME/CFS. Current research strongly suggests involvement of gastrointestinal tract and gut&#xD;
      microflora disturbances in the pathogenesis with strong evidence supporting the role of&#xD;
      imbalance of gut microflora, damaged gut barrier functions and dysfunctional immune&#xD;
      responses. There are some features shared with gastrointestinal conditions like irritable&#xD;
      bowel syndrome (IBS). GutMagnific™ is an evidence-based probiotic food supplement,&#xD;
      scientifically designed to be effective in correcting imbalances of the gut microflora,&#xD;
      repairing a damaged gut barrier and reducing inflammation. The strain combination in&#xD;
      GutMagnific™ has been carefully designed for its efficacy in IBS and therefore it can be&#xD;
      reasonably expected to be also effective in ME/CFS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2020</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Pre-masked randomized vegan capsules with probiotic &quot;GutMagnific&quot; in 2 different doses, or corresponding placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in ME/CFS symptoms</measure>
    <time_frame>At the baseline and weekly for 4 months</time_frame>
    <description>ME/CFS symptom rating scale filled up weekly by participants, graded 0-4 to evaluate degree of disease burden, according to the diagnostic Canadian Criteria. Higher score indicating worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Irritable Bowel Syndrome (IBS) symptoms</measure>
    <time_frame>At the baseline and weekly for 4 months</time_frame>
    <description>Questionnaire for IBS filled up by participants, graded 1-10 to evaluate degree of different bowel symptoms. Higher score indicating better condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the gastrointestinal symptoms based on Rome III criteria</measure>
    <time_frame>At the baseline and after 3 &amp; 4 months</time_frame>
    <description>Rome III questionnaire for IBS filled up by participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in health related quality of life (RAND 36-Item Health Survey)</measure>
    <time_frame>At the baseline and monthly for 4 months</time_frame>
    <description>RAND-36 questionnaire for health-related quality of life filled up by participants. The questionnaire evaluating eight health concepts: physical functioning, role limitations caused by physical health problem, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, and general health. Possible score is 0 (lowest) to 100 (highest) for each item.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>At the baseline and after 3 &amp; 4 months</time_frame>
    <description>HADS questionnaire for anxiety and depression filled up by participants.The questionnaire comprises questions for anxiety and depression. Each item on the questionnaire is scored from 0-3 and means that a person can score between 0 and 21 for either anxiety or depression. Higher score representing worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gut microbiota composition</measure>
    <time_frame>At the baseline and after 3 months</time_frame>
    <description>Fecal samples will be analysed using sequencing-based methods to monitor possible changes related to probiotic treatment. Samples taken prior to and after probiotic treatment in the same participant will be compared.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Myalgic Encephalomyelitis</condition>
  <condition>Chronic Fatigue Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo product is identical to active product in taste and appearance but without probiotic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose GutMagnific™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose GutMagnific™</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GutMagnific™ H.</intervention_name>
    <description>Vegan Capsules with active product, GutMagnific™ high dose</description>
    <arm_group_label>Treatment high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GutMagnific™ L.</intervention_name>
    <description>Vegan Capsules with active product, GutMagnific™ low dose</description>
    <arm_group_label>Treatment low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vegan capsules identical to active product in taste and appearance but without probiotic</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) at&#xD;
             Stora Sköndals Neurological Rehabilitation Clinic&#xD;
&#xD;
          -  Gastrointestinal complications similar to IBS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Consumption of any probiotics two weeks before enrolment&#xD;
&#xD;
          -  Consumption of other probiotic products during the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Julin, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurological Rehabilitation Clinic in Stora Sköndal</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myalgic Encephalomyelitis</keyword>
  <keyword>Chronic Fatigue Syndrome</keyword>
  <keyword>ME/CFS</keyword>
  <keyword>Post Viral Fatigue</keyword>
  <keyword>Post Viral Fatigue Syndrome</keyword>
  <keyword>Fatigue</keyword>
  <keyword>Post Exertional Malaise</keyword>
  <keyword>PEM</keyword>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>IBS</keyword>
  <keyword>Lactobacillus</keyword>
  <keyword>Probiotic</keyword>
  <keyword>GutMagnific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue Syndrome, Chronic</mesh_term>
    <mesh_term>Encephalomyelitis</mesh_term>
    <mesh_term>Myalgia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

